Discovery and preliminary structure–activity relationship studies on tecomaquinone I and tectol as novel farnesyltransferase and plasmodial inhibitors
作者:Melissa M. Cadelis、Marie-Lise Bourguet-Kondracki、Joëlle Dubois、Alexis Valentin、David Barker、Brent R. Copp
DOI:10.1016/j.bmc.2016.05.024
日期:2016.7
farnesyltransferase inhibitory activity in the low micromolar range. A preliminary structure–activity relationship (SAR) study has identified different structural requirements for anti-malarial activity in comparison to FTase activities for these classes of natural products. Our results identify tecomaquinone I as a novel scaffold from which more potent inhibitors of human and parasitic FTase could be developed.
生物合成的针对人法呢基转移酶(FTase)的苯并[ c ]亚甲基-7,10-二酮天然产物库的生物学筛选已确定替马醌I(IC 50为0.065± 0.004μM)是已鉴定出的更有效的天然产物抑制剂之一迄今为止。对同一文库针对恶性疟原虫的耐药菌株进行了抗血浆筛选,确定了结构相关的双色酚醇是一种中等活性的生长抑制剂,IC 50为3.44± 0.20μM 。基于苯并[ c]的两个新颖的类似物系列随后合成] chromene-7,10-dione支架,其中一种类似物在低微摩尔范围内表现出法尼基转移酶抑制活性。初步的结构-活性关系(SAR)研究确定了与此类天然产品的FTase活性相比,抗疟疾活性的不同结构要求。我们的研究结果表明tecomaquinone I是一种新型支架,可以从中开发出更有效的人和寄生FTase抑制剂。